-
For use in: dogs
Indicated for the treatment of pituitary-dependent hyperadrenocorticism in dogs and the treatment of hyperadrenocorticism due to adrenocortical tumor in dogs.
Active(s): Trilostane
Size: 30
Package Insert: Download
GROUP1329 -
For use in: dogs
Indicated for the treatment of pituitary-dependent hyperadrenocorticism in dogs and the treatment of hyperadrenocorticism due to adrenocortical tumor in dogs.
Active(s): Trilostane
Size: 30
Package Insert: Download
GROUP1303 -
For use in: dogs
Indicated for the treatment of pituitary-dependent hyperadrenocorticism in dogs and the treatment of hyperadrenocorticism due to adrenocortical tumor in dogs.
Active(s): Trilostane
Size: 30
Package Insert: Download
GROUP1303 -
For use in: dogs
Indicated for the treatment of pituitary-dependent hyperadrenocorticism in dogs and the treatment of hyperadrenocorticism due to adrenocortical tumor in dogs.
Active(s): Trilostane
Size: 30
Package Insert: Download
GROUP1303 -
For use in: dogs
Indicated for the treatment of pituitary-dependent hyperadrenocorticism in dogs and the treatment of hyperadrenocorticism due to adrenocortical tumor in dogs.
Active(s): Trilostane
Size: 30
Package Insert: Download
GROUP1303
Prescription Only
Important Safety Information
VETORYL Capsules
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. As with all drugs, side effects may occur. In field studies and post-approval experience, the most common side effects reported were: anorexia, lethargy/depression, vomiting, diarrhea, elevated liver enzymes, elevated potassium with or without elevated sodium, elevated BUN, decreased Na/K ratio, hypoadrenocorticism, weakness, elevated creatinine, shaking, and renal insufficiency. In some cases, death has been reported as an outcome of these adverse events. VETORYL Capsules are not for use in dogs with primary hepatic or renal disease, or in pregnant dogs. Refer to the prescribing information for complete details. VETORYL Capsules Package Insert
Navigation